Source: Annual Congress 2002 - Drug resistance
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Popov, I. Dorozhkova, V. Puzanov, M. Shulgina, L. Martinova (Moscow, Russia). External quality assessment of drug resistant TB testing in Russia. Eur Respir J 2002; 20: Suppl. 38, 2232

Member's Comments

No comment yet.

Related content which might interest you: Results of multicentral external quality assessment for M. tuberculosis drug susceptibility testing in Russia Source: Eur Respir J 2005; 26: Suppl. 49, 646s Year: 2005 Improving adherence in TB patients with alcohol and drug dependence through Sputnik initiative in Tomsk, Russia Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008 First outcomes of quality assurance system of TB laboratory diagnostics in orlovskaya oblast (Russia) Source: Eur Respir J 2002; 20: Suppl. 38, 167s Year: 2002 Comparative evaluation of the rapid diagnostic assays for detecting tuberculosis (TB) in a reference center for drug resistant TB in Brazil Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998-2000 Source: Eur Respir J 2003; 21: 129-134 Year: 2003 Outcomes of individualized treatment for MDR TB in Iran Source: Annual Congress 2007 - Medical and surgical treatment of susceptible and resistant tuberculosis Year: 2007 Drug resistant TB treatment outcomes in Novokuznetsk Source: Annual Congress 2007 - Epidemiological and clinical aspects of tuberculosis control Year: 2007 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 An interlaboratory quality control programme for the measurement of tuberculosis drugs Source: Eur Respir J 2015; 46: 268-271 Year: 2015 Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 Standardization and quality control to determine the drug resistance of M. tuberculosis in Kazakhstan Source: Eur Respir J 2002; 20: Suppl. 38, 358s Year: 2002 Improved treatment outcome of MDR-TB in Eastern Taiwan: Reducing default rate by DOTS Plus Source: Annual Congress 2013 –Tuberculosis: clinical epidemiology and public health Year: 2013 Results of the implementation of the WHO-recommended TB control strategy in Russia Source: Eur Respir J 2002; 20: Suppl. 38, 368s Year: 2002 Control of MDR-/XDR-TB and elimination of TB in Europe: status update Source: Annual Congress 2012 - Fighting MDR- and XDR-TB in Europe: from programme results to research implementation Year: 2012 Is standardized treatment appropriate for non-XDR multiple drug resistant TB? Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 The effectiveness of the treatment of patients with TB in the condition adapted DOTS-strategy in Ukraine Source: Annual Congress 2008 - Outcomes of tuberculosis treatment Year: 2008 Tuberculosis and intravenous drug users, impact of proximity measures in screening and treatment Source: International Congress 2015 – Screening strategies in TB Year: 2015